BRAF and malignant colon neoplasm: With regards to “BRAF-like” colon cancer, genome-wide shRNA screening revealed a selective vulnerability during mitotic progression when compared to non-BRAF-like colon cancer, which can be successfully targeted with the microtubule poison vinorelbine [62].